Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL).

Trial Profile

Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary)
  • Indications Aplastic anaemia; Myelodysplastic syndromes; T cell prolymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2013 Status changed from recruiting to discontinued as reported by M.D. Anderson Cancer Center.
    • 30 Sep 2013 Planned end date changed from 1 Aug 2014 to 1 Aug 2015 as reported by ClinicalTrials.gov.
    • 22 Nov 2012 Planned number of patients changed from 29 to 32 as reported by M.D. Anderson Cancer Center.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top